| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LMAN2L |
| Uniprot No | Q9H0V9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-348aa |
| 氨基酸序列 | MAATLGPLGSWQQWRRCLSARDGSRMLLLLLLLGSGQGPQQVGAGQTFEY LKREHSLSKPYQGVGTGSSSLWNLMGNAMVMTQYIRLTPDMQSKQGALWN RVPCFLRDWELQVHFKIHGQGKKNLHGDGLAIWYTKDRMQPGPVFGNMDK FVGLGVFVDTYPNEEKQQERVFPYISAMVNNGSLSYDHERDGRPTELGGC TAIVRNLHYDTFLVIRYVKRHLTIMMDIDGKHEWRDCIEVPGVRLPRGYY FGTSSITGDLSDNHDVISLKLFELTVERTPEEEKLHRDVFLPSVDNMKLP EMTAPLPPLSGLALFLIVFFSLVFSVFAIVIGIILYNKWQEQSRKRFY |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LMAN2L重组蛋白的模拟参考文献(注：内容为假设性示例，非真实文献)：
1. **文献名称**：*Structural Insights into LMAN2L as a Carbohydrate-Binding Protein*
**作者**：Zhang Y. et al.
**摘要**：本研究解析了重组LMAN2L蛋白的晶体结构，揭示了其保守的凝集素结构域与甘露糖类糖基化位点的特异性结合能力，提示其在细胞内糖蛋白质量控制中的作用。
2. **文献名称**：*LMAN2L Facilitates ER-to-Golgi Transport of Glycoproteins via Recombinant Interaction Assays*
**作者**：Wang H. et al.
**摘要**：通过体外重组蛋白实验，发现LMAN2L与特定运输囊泡组分相互作用，调控内质网至高尔基体的糖蛋白转运，敲除细胞模型中显示分泌蛋白成熟延迟。
3. **文献名称**：*LMAN2L Recombinant Protein as a Potential Biomarker in Hepatocellular Carcinoma*
**作者**：Liu X. et al.
**摘要**：利用重组LMAN2L蛋白进行血清学分析，发现其在肝癌患者中表达异常，并可能通过调控TGF-β通路影响肿瘤侵袭性，为潜在诊断标志物。
4. **文献名称**：*Functional Characterization of LMAN2L in Lysosomal Enzyme Trafficking*
**作者**：Kim S. et al.
**摘要**：基于重组LMAN2L的体外结合实验，证明其参与溶酶体酶前体的识别与靶向运输，功能缺失导致溶酶体贮积症相关表型。
(注：以上内容为模拟生成，实际研究需参考真实数据库如PubMed。)
LMAN2L (Lectin, Mannose Binding 2 Like), also known as ERGIC-53-like or VIP36-like, is a member of the LMAN1 protein family, characterized by carbohydrate-binding lectin domains involved in intracellular glycoprotein trafficking. Structurally, it contains a single transmembrane domain, a coiled-coil region for oligomerization, and a carbohydrate recognition domain (CRD) that binds mannose-rich glycans. Unlike its well-studied homolog LMAN1 (ERGIC-53), which facilitates glycoprotein transport between the endoplasmic reticulum (ER) and Golgi apparatus, LMAN2L is proposed to function in alternative pathways, potentially regulating ER-associated degradation (ERAD) or participating in post-Golgi vesicular transport.
Recombinant LMAN2L is engineered using expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified protein for functional studies. Its production often involves codon-optimized cDNA cloning, affinity tag incorporation (e.g., His-tag), and purification via chromatography. Research applications include elucidating its role in glycoprotein quality control, interactions with misfolded proteins, and modulation of cellular stress responses. Studies suggest LMAN2L may act as a tumor suppressor, with reduced expression observed in certain cancers, influencing metastasis and cell proliferation pathways. Additionally, it has been implicated in neurological disorders, though mechanistic insights remain limited. Recombinant LMAN2L serves as a critical tool for structural analysis (e.g., crystallography), antibody development, and high-throughput screening for therapeutic targeting. Ongoing research aims to clarify its physiological ligands, regulatory networks, and potential as a biomarker or drug target in disease contexts.
×
